Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients

Pharmacotherapy

Volumn 25, Issue 5 I, 2005, Pages 646-653

  Wu, Fe Lin Lin ^a,b   Tsai, Meng Kun ^a,b   Rhei Long Chen, Russel ^c   Sun, Shao Wen ^a   Huang, Jin Ding ^d   Hu, Rey Heng ^a,b   Chen, Kuo Hsin ^e   Lee, Po Huang ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TAJEN INSTITUTE OF TECHNOLOGY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cyclosporine; Drug interactions; Kidney transplantation; Pharmacokinetics; Sirolimus; Tacrolimus

Indexed keywords

ACICLOVIR; AMLODIPINE; AMLODIPINE BESYLATE; BAKTAR; BETAXOLOL; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOSPORIN A; FELODIPINE; GANCICLOVIR; METHYLPREDNISOLONE SODIUM SUCCINATE; NYSTATIN; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE REGIMEN; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER FUNCTION; LIVER TOXICITY; MALE; MICROEMULSION; MULTIPLE DRUG DOSE; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; TAIWAN; TEACHING HOSPITAL;

ADULT; CALCINEURIN; CYCLOSPORINE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; SIROLIMUS; TACROLIMUS;

EID: 18044379147     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.5.646.63593     Document Type: Article

References (27)

1. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335-40.
2. Zimmerman JJ, Kahan BD. The pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997;37:405-15.
3. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche H-U, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998;66:1040-6.
4. Turgeon DK, Leichtman AB, Lown KS, et al. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 1994;56:253-60.
5. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing FK. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61.
6. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 1996;118:1841-7.
7. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60.
8. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 2000;68:98-103.
9. Yatscoff RW. Pharmacokinetics of rapamycin. Transplant Proc 1996;28:970-3.
10. Lampen A, Christians U, Guengerich FP, et. al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995;23:1315-24.
11. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000;22:B101-21.
12. Anonymous. Physicians' desk reference, 57th ed. Montvale, NJ: Medical Economics Co., 2003:3469-74.
13. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003;18:i12-15.
14. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Long-term pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients. Ther Drug Monit 2003;25:447-51.
15. McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002;24:346-50.
16. Kaplan B, Meier-Kriesche H-U, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998;63:48-53.
17. French DC, Saltzgueber M, Hicks DR, Cowper AL, Holt DW. HPLC assay with ultraviolet detection for therapeutic drug monitoring of sirolimus. Clin Chem 2001;47:1316-19.
18. U.S. Food and Drug Administration. Center for Drug Administration and Research. Guidance for industry bioanalytical method validation, May, 22, 2001. Available from www.fda.gov/cder/guidance/4252fnl.htm. Accessed June 2, 2002.
19. Tsai MK, Chueh SC, Hu RH, Lee PH. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection. J Formos Med Assoc 2003;102:91-6.
20. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000;14:97-109.
21. McGregor DO, Bailey RR, Robson RA. Amlodipine has a minor effect on cyclosporine metabolism [letter]. Clin Nephrol 1997;48:336.
22. Pfammatter JP, Clericetti-Affolter C, Truttmann AC, Busch K, Laux-End R, Bianchetti MG. Amlodipine once-daily in systemic hypertension. Eur J Pediatr 1998;157:618-21.
23. Madsen JK, Jensen JD, Jensen LW, Pedersen EB. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur J Clin Pharmacol 1996;50:203-8.
24. Brunner LJ, Bennett WM, Koop DR. Cyclosporine suppresses rat hepatic cytochrome P450 in a time-dependent manner. Kidney Int 1998;54:216-23.
25. Demeule M, Laplante A, Sepehr-Araé A, et al. Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites. Biochem Cell Biol 1999;77:47-58.
26. Levêque D, Jehl F. P-glycoprotein and pharmacokinetics. Anticancer Res 1995;15:331-6.
27. Deters M, Nolte K, Kirchner G, Resch K, Kaever V. Comparative study analyzing effects of sirolimus-cyclosporine and sirolimus-tacrolimus combinations on bile flow in the rat. Digest Dis Sci 2001;46:2120-6.